Skip to main content

Advertisement

Table 2 Patient characteristics by HCV genotype

From: Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

  HCV genotype (no. of patients)  
Characteristics 1a (n = 32) 1b (n = 30)
Gender   
Male 22 (68.7%) 17 (56.6%)
Female 10 (31.2%) 13 (43.3%)
Demographics   
Italian 31 (96.8%) 25 (83.3%)
Others 1 (3.1%) 5 (16.6%)
No. of HIV-1/HCV co- infected patients receiving HAART 8 (25%) 2 (6.6%)
Median HCV viral load (UI/ml) in HCV mono-infected patients 1,614,064 (range 6,743-7,985,320) 991,975 (range 3,470-4,381,000)
Median HCV viral load (UI/ml) in HCV/HIV co-infected patients 2,367,635 (range 46,801-7,985,320) 473,597 (range 46,801-900,393)
No. of patients naïve to peg IFN/RBV 26 (81.2%) 29 (96.6%)
  1. HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; HAART, Highly Active Anti-Retroviral Therapy; IFN, Interferon; RBV, Ribavirin.